Cost Curve News - News - https://www.costcurvenews.com/blog/page/8/

The UK Abandoned Biopharma Innovation. Now Biopharma Is Abandoning the UK

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

Was the White House’s Attack on DTC Advertising Fueled by Robots?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

340B Remains In the Spotlight, With New Legislation, Court Battles, and the Pending Rebate Model Launch

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

I’m Not Sure Where to Begin Today. Health Costs? 340B? DTC Ads? Patent Shenanigans?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

Hospitals Allege 340B Collusion in a Context-Free Letter to the DOJ and FTC

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

The Complexity of COVID Vaccine Regulation Is Hampering Patient Access

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

What Yesterday’s RFK Jr. Hearing Did — and Did Not — Illuminate

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

More on the Biggest Story of Fall 2025: The Growth in Health Care Spending

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

The Many Twists in the Gordian Knot that Is Obesity-Med Coverage

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

Cost Curve News

Tariffs Are Illegal (Maybe) … But That Might Not Matter for Meds

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

4 months ago

Keep Reading

The UK Abandoned Biopharma Innovation. Now Biopharma Is Abandoning the UK

Was the White House’s Attack on DTC Advertising Fueled by Robots?

340B Remains In the Spotlight, With New Legislation, Court Battles, and the Pending Rebate Model Launch

I’m Not Sure Where to Begin Today. Health Costs? 340B? DTC Ads? Patent Shenanigans?

Hospitals Allege 340B Collusion in a Context-Free Letter to the DOJ and FTC

The Complexity of COVID Vaccine Regulation Is Hampering Patient Access

What Yesterday’s RFK Jr. Hearing Did — and Did Not — Illuminate

More on the Biggest Story of Fall 2025: The Growth in Health Care Spending

The Many Twists in the Gordian Knot that Is Obesity-Med Coverage

Tariffs Are Illegal (Maybe) … But That Might Not Matter for Meds

Latest Posts

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Popular

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Happy Festivus! Cost Curve Readers Have Some Grievances They’d Like to Air.

Latest News

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Subcribe To Newsletter